YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy

Introduction: Prostate cancer is the second leading cause of cancer death among men in the United States. Castration-Resistant Prostate Cancer (CRPC) often develops resistance to androgen deprivation therapy. Resistance in CRPC is often driven by AR variants and glucocorticoid receptor (GR). Thus, d...

Descripción completa

Detalles Bibliográficos
Autores principales: Lam, Wing, Arammash, Mohammad, Cai, Wei, Guan, Fulan, Jiang, Zaoli, Liu, Shwu-Huey, Cheng, Peikwen, Cheng, Yung-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582333/
https://www.ncbi.nlm.nih.gov/pubmed/37860121
http://dx.doi.org/10.3389/fphar.2023.1244655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582333/
https://www.ncbi.nlm.nih.gov/pubmed/37860121
http://dx.doi.org/10.3389/fphar.2023.1244655

Ejemplares similares